Palmitoyllactic acid, (S)-

We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596503

CAS#: 358632-58-3

Description: Palmitoyllactic acid, (S)- is a bioactive chemical.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2020-07-11. Prices are subject to change without notice.

Palmitoyllactic acid, (S)- is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 596503
Name: Palmitoyllactic acid, (S)-
CAS#: 358632-58-3
Chemical Formula: C19H36O4
Exact Mass: 328.2614
Molecular Weight: 328.49
Elemental Analysis: C, 69.47; H, 11.05; O, 19.48


Synonym: Palmitoyllactic acid, (S)-; L-2-o-palmitoyllactic acid;

IUPAC/Chemical Name: (S)-2-(palmitoyloxy)propanoic acid

InChi Key: QEYBJRUFQPDBLY-KRWDZBQOSA-N

InChi Code: InChI=1S/C19H36O4/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18(20)23-17(2)19(21)22/h17H,3-16H2,1-2H3,(H,21,22)/t17-/m0/s1

SMILES Code: CCCCCCCCCCCCCCCC(O[C@H](C(O)=O)C)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Scholtysek P, Shah SW, Müller SS, Schöps R, Frey H, Blume A, Kressler J. Unusual triskelion patterns and dye-labelled GUVs: consequences of the interaction of cholesterol-containing linear-hyperbranched block copolymers with phospholipids. Soft Matter. 2015 Aug 14;11(30):6106-17. doi: 10.1039/c5sm01017a. Epub 2015 Jul 2. PubMed PMID: 26133098.

2: Cucu T, Shrestha K, De Meulenaer B. Development of a quantitative GC-FID method for the determination of stearoyl-lactylates (E481/482) in foods. Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2014;31(12):1929-38. doi: 10.1080/19440049.2014.971445. Epub 2014 Nov 3. PubMed PMID: 25268514.

3: Zhu J, Wu Y, Tang Q, Leng Y, Cai W. The effects of choline on hepatic lipid metabolism, mitochondrial function and antioxidative status in human hepatic C3A cells exposed to excessive energy substrates. Nutrients. 2014 Jul 9;6(7):2552-71. doi: 10.3390/nu6072552. PubMed PMID: 25010553; PubMed Central PMCID: PMC4113756.

4: Modrego J, de las Heras N, Zamorano-León JJ, Mateos-Cáceres PJ, Martín-Fernández B, Valero-Muñoz M, Lahera V, López-Farré AJ. Changes in cardiac energy metabolic pathways in overweighed rats fed a high-fat diet. Eur J Nutr. 2013 Mar;52(2):847-56. doi: 10.1007/s00394-012-0392-7. Epub 2012 Jun 14. PubMed PMID: 22695689.

5: Nikolić N, Bakke SS, Kase ET, Rudberg I, Flo Halle I, Rustan AC, Thoresen GH, Aas V. Electrical pulse stimulation of cultured human skeletal muscle cells as an in vitro model of exercise. PLoS One. 2012;7(3):e33203. doi: 10.1371/journal.pone.0033203. Epub 2012 Mar 22. Erratum in: PLoS One. 2013 Mar 4;8(3):null. PubMed PMID: 22457744; PubMed Central PMCID: PMC3310863.

6: Simar D, Chen H, Lambert K, Mercier J, Morris MJ. Interaction between maternal obesity and post-natal over-nutrition on skeletal muscle metabolism. Nutr Metab Cardiovasc Dis. 2012 Mar;22(3):269-76. doi: 10.1016/j.numecd.2010.11.007. Epub 2011 Jan 3. PubMed PMID: 21208789.

7: Ahmad S, Johnston BF, Mackay SP, Schatzlein AG, Gellert P, Sengupta D, Uchegbu IF. In silico modelling of drug-polymer interactions for pharmaceutical formulations. J R Soc Interface. 2010 Aug 6;7 Suppl 4:S423-33. doi: 10.1098/rsif.2010.0190.focus. Epub 2010 Jun 2. PubMed PMID: 20519214; PubMed Central PMCID: PMC2943894.

8: Fediuc S, Pimenta AS, Gaidhu MP, Ceddia RB. Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells. J Cell Physiol. 2008 May;215(2):392-400. PubMed PMID: 17960559.

9: Planavila A, Alegret M, Sánchez RM, Rodríguez-Calvo R, Laguna JC, Vázquez-Carrera M. Increased Akt protein expression is associated with decreased ceramide content in skeletal muscle of troglitazone-treated mice. Biochem Pharmacol. 2005 Apr 15;69(8):1195-204. PubMed PMID: 15794940.

10: Ponsot E, Zoll J, N'guessan B, Ribera F, Lampert E, Richard R, Veksler V, Ventura-Clapier R, Mettauer B. Mitochondrial tissue specificity of substrates utilization in rat cardiac and skeletal muscles. J Cell Physiol. 2005 Jun;203(3):479-86. PubMed PMID: 15521069.

11: Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, Hoppel CL, Imai M, Rastogi S, Sabbah HN, Stanley WC. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol. 2004 Oct;287(4):H1538-43. Epub 2004 Jun 10. PubMed PMID: 15191896.

12: Le-Tien C, Millette M, Mateescu MA, Lacroix M. Modified alginate and chitosan for lactic acid bacteria immobilization. Biotechnol Appl Biochem. 2004 Jun;39(Pt 3):347-54. PubMed PMID: 15154848.

13: Ikushiro H, Hayashi H, Kagamiyama H. Reactions of serine palmitoyltransferase with serine and molecular mechanisms of the actions of serine derivatives as inhibitors. Biochemistry. 2004 Feb 3;43(4):1082-92. PubMed PMID: 14744154.

14: Iemitsu M, Miyauchi T, Maeda S, Sakai S, Fujii N, Miyazaki H, Kakinuma Y, Matsuda M, Yamaguchi I. Cardiac hypertrophy by hypertension and exercise training exhibits different gene expression of enzymes in energy metabolism. Hypertens Res. 2003 Oct;26(10):829-37. PubMed PMID: 14621187.

15: Chandler MP, Chavez PN, McElfresh TA, Huang H, Harmon CS, Stanley WC. Partial inhibition of fatty acid oxidation increases regional contractile power and efficiency during demand-induced ischemia. Cardiovasc Res. 2003 Jul 1;59(1):143-51. PubMed PMID: 12829185.

16: Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002 Jul 30;106(5):606-12. PubMed PMID: 12147544.

17: Kong JY, Rabkin SW. Palmitate-induced cardiac apoptosis is mediated through CPT-1 but not influenced by glucose and insulin. Am J Physiol Heart Circ Physiol. 2002 Feb;282(2):H717-25. PubMed PMID: 11788422.

18: Kiran KR, Divakar S. Lipase catalyzed synthesis of organic acid esters of lactic acid in non-aqueous media. J Biotechnol. 2001 May 4;87(2):109-21. PubMed PMID: 11278035.

19: Knipp GT, Ho NF, Barsuhn CL, Borchardt RT. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J Pharm Sci. 1997 Oct;86(10):1105-10. PubMed PMID: 9344165.

20: Portilla D. Carnitine palmitoyl-transferase enzyme inhibition protects proximal tubules during hypoxia. Kidney Int. 1997 Aug;52(2):429-37. PubMed PMID: 9263998.